Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma

11 Apr 2006

Abstract excerpt

BACKGROUND: Methylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase (MGMT) causes gene silencing. This epigenetic modification has been associated with a favorable prognosis in adult patients with glioblastoma (GBM) who receive temozolomide and other alkylating agents. We explored MGMT promoter methylation in pediatric GBM and its relationship to survival and temozolomide sensitivity. PROCEDURE:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment
Share to Hedgehog Signaling Pathway Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16609952
DOI: 10.1002/pbc.20803

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastomaPMID 16609952Read ↗

MGMT Gene Silencing and Benefit from Temozolomide in GlioblastomaSemantic proximity Read ↗

O6-Methylguanine-DNA Methyltransferase (MGMT) mRNA Expression Predicts Outcome in Malignant Glioma Independent of MGMT Promoter MethylationSemantic proximity Read ↗

The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.Semantic proximity Read ↗

CpG Island Hypermethylation of the DNA Repair Enzyme Methyltransferase Predicts Response to Temozolomide in Primary GliomasSemantic proximity Read ↗

MGMT Promoter Methylation: Prognostication beyond Treatment ResponseSemantic proximity Read ↗

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapySemantic proximity Read ↗

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomideSemantic proximity Read ↗

O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patientsSemantic proximity Read ↗

Clinical Trial Substantiates the Predictive Value of <b> <i>O-6-Methylguanine-DNA Methyltransferase</i> </b> Promoter Methylation in Glioblastoma Patients Treated with TemozolomideSemantic proximity Read ↗

THE CORRELATION AND PROGNOSTIC SIGNIFICANCE OF MGMT PROMOTER METHYLATION AND MGMT PROTEIN IN GLIOBLASTOMASSemantic proximity Read ↗

Comprehensive Analysis of MGMT Promoter Methylation: Correlation with MGMT Expression and Clinical Response in GBMSemantic proximity Read ↗

Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: A Portuguese multicentre studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.